These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 28428503)

  • 1. [Cancer Immunotherapy Utilizing T Cell Receptor Gene Engineering].
    Ikeda H
    Gan To Kagaku Ryoho; 2017 Apr; 44(4):273-277. PubMed ID: 28428503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Adoptive immunotherapy utilizing cancer antigen-specific T-cell receptors].
    Tanimoto K; Fujiwara H
    Rinsho Ketsueki; 2016; 57(11):2355-2364. PubMed ID: 27941286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.
    Berry LJ; Moeller M; Darcy PK
    Tissue Antigens; 2009 Oct; 74(4):277-89. PubMed ID: 19775368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies to genetically engineer T cells for cancer immunotherapy.
    Spear TT; Nagato K; Nishimura MI
    Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
    Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK
    Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor T Cell Therapy in Hematology.
    Ataca P; Arslan Ö
    Turk J Haematol; 2015 Dec; 32(4):285-94. PubMed ID: 26377367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of adoptive cell therapy for cancer: a clinical perspective.
    Hawkins RE; Gilham DE; Debets R; Eshhar Z; Taylor N; Abken H; Schumacher TN; ATTACK Consortium
    Hum Gene Ther; 2010 Jun; 21(6):665-72. PubMed ID: 20408760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced T cell receptor gene therapy for cancer.
    Kieback E; Uckert W
    Expert Opin Biol Ther; 2010 May; 10(5):749-62. PubMed ID: 20201709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive T-cell therapy for cancer: The era of engineered T cells.
    Bonini C; Mondino A
    Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent advances and future challenges in cancer immunotherapy].
    Okuyama N; Tamada K; Tamura H
    Rinsho Ketsueki; 2016; 57(11):2388-2395. PubMed ID: 27941290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T Cell Therapy: A Game Changer in Cancer Treatment.
    Almåsbak H; Aarvak T; Vemuri MC
    J Immunol Res; 2016; 2016():5474602. PubMed ID: 27298832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy.
    Thistlethwaite F; Mansoor W; Gilham DE; Hawkins RE
    Curr Opin Mol Ther; 2005 Feb; 7(1):48-55. PubMed ID: 15732529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gene-modified T cell therapy].
    Ikeda H
    Nihon Rinsho; 2017 Feb; 75(2):275-280. PubMed ID: 30562864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the efficacy and safety of engineered T cell therapy for cancer.
    Shi H; Liu L; Wang Z
    Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
    Peinert S; Kershaw MH; Prince HM
    Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
    [No Abstract]   [Full Text] [Related]  

  • 19. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
    Houot R; Schultz LM; Marabelle A; Kohrt H
    Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell engineering for cancer immunotherapy.
    Sadelain M
    Cancer J; 2009; 15(6):451-5. PubMed ID: 20010162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.